Pharmaceutical Gummy Development FAQ | Pharmmies

---

 Pharmmies is a specialized pharmaceutical drug-product development company focused on API-containing  gummy dosage forms. We lead programs from feasibility, formulation and taste masking through prototype  development, pilot scale-up, analytical and regulatory planning, GMP technology transfer, commercial  manufacturing and supply coordination. Activities are performed directly or through qualified partners  according to the needs of each program. Pharmmies does not develop standard confectionery or dietary supplement gummies 

 Pharmaceutical gummies are chewable oral dosage forms containing an active pharmaceutical ingredient. They are  designed to deliver a defined drug dose in a palatable format and may address swallowing or acceptability challenges  associated with tablets, capsules or liquid medicines. Like any drug product, they require appropriate formulation,  analytical controls, stability, packaging and regulatory development 

 No. Feasibility depends on dose load, taste, solubility, particle size, heat and pH sensitivity, interactions with the gummy  matrix, dissolution requirements, stability, unit size and the intended regulatory pathway. Each API should be assessed  before substantial development investment. 

The main challenges typically include dose loading and content uniformity, taste masking, API release and dissolution,  process conditions, moisture and texture control, microbial risk, packaging, shelf-life and scale-up. The relative  importance of each risk depends on the API and target product profile 

Programs normally begin with a feasibility and product-definition phase. This phase reviews the API, dose, target  population, reference products, target market, preliminary regulatory assumptions, technical risks and an initial  development route. Prototype work is then proposed based on the findings. 

 Yes. Pharmmies can take a program beyond development by selecting and coordinating qualified GMP  manufacturers, analytical laboratories, packaging suppliers and supply partners. Pharmmies remains the  accountable program lead; manufacturing, testing and distribution activities are performed by appropriately  qualified and authorized partners  

Yes. Pharmmies can support CDMO selection, transfer-package preparation, process and material definition,  analytical development and validation, stability planning, engineering and GMP batch readiness, packaging  strategy and cross-functional execution. GMP manufacturing and testing are performed by appropriately  qualified partners under the coordinated program. 

Yes, subject to program-specific regulatory assessment. The required pathway depends on the active ingredient,  intended claims, reference product, dosage-form differences and target market. Regulatory assumptions should be  validated early with appropriately qualified regulatory experts 

Pharmmies has development-stage experience with acetaminophen/paracetamol, ibuprofen and diphenhydramine  gummy concepts, including formulation, taste-masking and pilot-scale activities. These programs should not be  interpreted as approved or commercially available products. 

Please provide the API, target dose, target patient population, intended market, reference product if applicable, current  development stage, expected annual volume and the specific support required. Confidential information can be discussed  after an appropriate confidentiality agreement is in place